Related Experiment Video
Updated: Jan 18, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
6.0K
Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study.
Soumyava Basu1, Sucheta Ireni1, Mudit Tyagi1,2
1Saroja A Rao Center for Uveitis, LV Prasad Eye Institute, Hyderabad, India.
Ocular Immunology and Inflammation
|May 27, 2025
Summary
Low-dose subconjunctival adalimumab (5 mg) is safe and effective for non-infectious uveitis (NIU) refractory to conventional therapy. This treatment improved inflammatory scores and visual acuity in patients with persistent intraocular inflammation.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Non-infectious uveitis (NIU) poses a significant challenge, especially when refractory to conventional immunomodulatory therapy (IMT).
- Persistent intraocular inflammation can lead to vision loss and requires novel therapeutic approaches.
Purpose of the Study:
- To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with NIU.
- To assess the impact of subconjunctival adalimumab on inflammatory markers and visual acuity in refractory NIU cases.
Main Methods:
- A prospective, noncomparative, interventional case series involving five patients with bilateral panuveitis.
- Patients received three doses of subconjunctival adalimumab (5 mg/0.1 mL) at two-week intervals, with a 24-week follow-up period.
Main Results:
- No serious adverse events such as conjunctival congestion, corneal issues, or elevated intraocular pressure were reported.
- Three out of five patients showed improvement in inflammatory scores and best-corrected visual acuity (BCVA).
- No baseline factors like cystoid macular edema or vitreous haze explained the BCVA improvement in the responding patients.
Conclusions:
- Subconjunctival administration of 5 mg adalimumab is a safe treatment option for NIU.
- This method demonstrates preliminary efficacy in managing NIU refractory to conventional IMT.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
01:28Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K